Superworth

Zentalis Pharmaceuticals price to book ratio ZNTL

Market value divided by the book value of the company's net assets, since 2020.

Today, Nov 2, 2026
0.9×
6-year median
2.5×
Against its 6-year history
29th
percentile: 0 is its lowest day, 100 its highest
6-year range
0.2× to 16.6×
Peer median
1.5×

Zentalis Pharmaceuticals' price to book ratio is 0.9× as of Nov 2, 2026.

That is below its 6-year median of 2.5×, lower than on 71% of days in the last 6 years.

Over that time it ranged from 0.2× in Apr 2025 to 16.6× in Nov 2021.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.9×0.4×2.2×
20250.4×0.2×0.7×
20240.6×0.5×2.6×
20232.2×1.4×4.6×
20222.7×2.4×8.0×
20219.7×4.3×16.6×
20206.2×4.8×7.9×

Against its peers

Companies in Drug Manufacturers - General nearest Zentalis Pharmaceuticals' size, closest first, today.

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Zentalis Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.